MADRID, 14 Dic. (EUROPA PRESS) –
Atrys Health has completed the sale of 100% of its compliance subsidiary Conversia for a total amount of 55 million euros, as reported by the company this Thursday.
In this sense, the company has completed the sale of the remaining 75.01% of Conversia’s shares to the company Arraigo Midco, controlled by Arraigo NW Segundo, for 35 million euros, after receiving a binding offer on November 20.
Specifically, the sale of 75.01% of Conversia’s shares, together with that of 24.99% of the company carried out on December 22, 2022, will allow Atrys to obtain a total amount of 55 million euros for the sale of 100% of Conversia.
This divestment, as the firm detailed at the time, is part of Atrys’ strategic plan “which focuses its activity on the ‘Precision Medicine’ and ‘Prevention Medicine’ business segments.”
The funds obtained from the sale of 75.01% of Conversia will be used to reduce the financial debt of the Atrys group.
